Canadian Oncology Nursing Journal

Revue canadienne de soins infirmiers en oncologie

Volume 35, Issue 4 • 2025
eISSN: 2368-8076

CANO ACIO
Canadian Association of Nurses in Oncology
Association canadienne des infirmières en oncologie

Advancements in oncology: Innovations in prevention and early detection

by Kirolos Eskandar

ABSTRACT

In recent years, oncology has witnessed significant advancements in prevention strategies and early detection technologies, profoundly impacting patient outcomes. This literature review aims to equip oncology nurses, particularly those new to the field, with a comprehensive understanding of these developments. The review delves into the implementation of vaccines, lifestyle modifications, and cutting-edge screening technologies, highlighting the role of genetic and genomic screening in identifying cancer susceptibility, accompanied by ethical considerations. Furthermore, the review critically examines the contributions of oncology nursing in promoting these preventive measures and underscores the importance of public health policies in fostering their adoption. By focusing on these advancements, the review provides a detailed analysis of the current landscape and future prospects in oncology prevention and early detection, emphasizing their significance in enhancing patient care and survival rates.

Keywords: cancer prevention, early detection, oncology nursing, screening technologies, cancer vaccines, genetic screening, AI in oncology, ethical considerations.

INTRODUCTION

The significance of prevention and early detection in cancer management cannot be overstated. This review is designed to provide oncology nurses, particularly those new to the field, with a thorough overview of recent advancements in prevention strategies and early detection technologies. It explores the implementation of vaccines, lifestyle modifications, and screening technologies, while also critically examining the role of genetic and genomic screening in cancer prevention. The review integrates discussions on AI innovations and ethical considerations within each topic to offer a critical perspective on their impact on clinical practice.

Early detection has consistently been shown to enhance patient outcomes by identifying malignancies at stages where treatment is more effective. For instance, the early detection of breast and cervical cancers through regular screening has played a pivotal role in reducing mortality and improving survival outcomes (Dillner, 2019). Similar benefits have been observed with screening programs for colorectal and lung cancers, underscoring the critical importance of these interventions in public health.

AUTHOR NOTES

Kirolos Eskandar, Diakonie Klinik Mosbach – Germany

+49 1775965567 / **kiroloss.eskandar@gmail.com**

ORCID ID: https://orcid.org/0000-0003-0085-3284

DOI:10.5737/23688076354571

The evolution of cancer prevention strategies is closely tied to the development of vaccines and lifestyle modification programs. Vaccines, such as the Human Papillomavirus (HPV) and Hepatitis B vaccines, have been instrumental in preventing virus-related cancers, including cervical and liver cancers. These advancements marked a significant shift in cancer prevention, particularly through the role of immunization in reducing cancer risk. Lifestyle modifications, such as tobacco cessation, dietary changes, and increased physical activity, have also been central to cancer prevention efforts. Tobacco control measures have led to a dramatic reduction in smoking rates, and consequently, in the incidence of lung and other smoking-related cancers. Smoke-free policies and public health campaigns have been effective in this regard (Dillner, 2019).

Screening technologies have progressed from simple physical examinations to sophisticated imaging and molecular diagnostic techniques. Innovations, such as low dose computed tomography (CT) for lung cancer and mammography for breast cancer, have become standard practice, significantly enhancing early detection capabilities (Division of Cancer Prevention, 2024). The development of biomarkers has further opened new avenues for early cancer detection, allowing cancers to be identified at the molecular level before clinical symptoms appear (National Cancer Institute, 2024).

The historical context of cancer prevention and screening highlights continuous advancements in technology and public health policies aimed at reducing the cancer burden. From rudimentary screening methods to advanced genomic and imaging techniques, substantial progress has been made, improving survival rates and enhancing the quality of life through earlier, less invasive treatments.

METHODOLOGY

A systematic approach was utilized for this literature review, adhering to the PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) guidelines to ensure a rigorous and comprehensive search process. The review focused on advancements in cancer prevention and early detection technologies, with a particular emphasis on innovations that are relevant to oncology nursing.

Search Strategy and Databases

A thorough search was conducted across multiple reputable databases, including PubMed, Scopus, Web of Science, and Google Scholar. The search strategy was designed to capture a wide range of studies, encompassing various aspects of oncology prevention and early detection. Specific keywords used in the search included “Cancer prevention,” “Early detection,” “Oncology nursing,” “Screening technologies,” “Cancer vaccines,” “Genetic screening,” and “AI in oncology.” These

keywords were chosen to ensure a comprehensive coverage of the literature, targeting studies that address both traditional and emerging approaches in oncology.

Inclusion and Exclusion Criteria:

The inclusion criteria for this review were as follows:

1. **Language:** Publications were limited to those available in English to maintain consistency in the analysis.
2. **Focus:** Studies were selected based on their relevance to advancements in oncology, particularly those reporting on innovations in prevention strategies and early detection technologies.
3. **Publication Type:** The review prioritized original research articles, systematic reviews, and meta-analyses. Studies that primarily referenced organizational guidelines without supporting original data were excluded, to maintain the focus on primary sources of evidence.

Study Selection and Evaluation

The initial search yielded 159 articles. After removing duplicates, 44 unique articles met the inclusion criteria and were subjected to further scrutiny. These articles underwent a rigorous evaluation process, which included a detailed assessment of their titles, abstracts, and full texts. The evaluation ensured that each study aligned with the review's objectives and met the established inclusion criteria.

To provide a robust foundation for the review, the emphasis was placed on studies that presented original research data or offered critical analyses of emerging technologies and strategies in oncology. Where organizational websites were referenced, they were used to supplement primary sources or provide context but were not relied upon as the primary source of evidence.

Study Selection Process: The PRISMA flow diagram (Figure 1) provides an overview of the study selection process, illustrating the number of records identified, screened, and ultimately included in the review. The diagram also outlines the reasons for excluding studies at each stage, ensuring transparency and reproducibility of the review process.

Analysis Process: The selected articles were analyzed using a thematic synthesis approach to identify recurring themes, advancements, and emerging trends in oncology prevention and early detection. Data extraction involved cataloging information on methodologies, key findings, technological innovations, and the implications for clinical practice. The articles were grouped into major thematic categories, such as cancer vaccines, lifestyle modifications, and advancements in screening technologies, allowing for a detailed comparison of findings.

Quantitative data were collated to provide aggregated insights, highlighting commonalities in study outcomes and supporting meta-analytical observations where applicable. The analysis process also involved evaluating the quality of the included studies based on their methodology, sample size, and the robustness of their findings. This ensured that the synthesis presented in the results section was based on reliable and high-quality evidence.

Figure 1

Overview of PRISMA Flowchart



RESULTS

The results are presented in a structured format, emphasizing thematic categories including

- Cancer Vaccines: Examining the efficacy of prophylactic and therapeutic vaccines, including the HPV and Hepatitis B vaccines, and emerging mRNA-based cancer vaccines.
- Lifestyle Modifications: Analyzing the impact of dietary changes, physical activity, and smoking cessation on cancer prevention.
- Advancements in Screening Technologies: Highlighting innovations such as liquid biopsies, AI-driven imaging, and genetic screening, including their clinical implications and challenges.

Each section provides an overview of significant findings, including the potential benefits, limitations, and ethical considerations of these advancements. The results also explore the ethical challenges in screening and prevention, the role of oncology nursing in promoting these strategies, and discusses the implications for future research and public health policy.

SUMMARY OF CURRENT TRENDS BASED ON REVIEW ANALYSIS

Cancer Vaccines: Prophylactic and Therapeutic Approaches

Cancer vaccines represent a promising frontier in oncology, with prophylactic and therapeutic applications each offering unique benefits and challenges. Prophylactic cancer vaccines aim to prevent cancer by targeting infectious agents associated with cancer development, while therapeutic vaccines are designed to treat existing cancers by stimulating the immune system to target and destroy cancer cells.

One of the most notable successes in prophylactic cancer vaccines is the HPV vaccine. Approved by the FDA in 2006, this vaccine targets high-risk HPV strains responsible for the majority of cervical cancers, as well as other cancers (e.g., anus, penis, and oropharynx). The introduction of the HPV vaccine has led to a significant reduction in HPV-related cancers, particularly when administered before exposure to the virus, typically in preadolescents (Arbyn et al., 2020). Despite its success, challenges remain in administering the vaccine. Disparities in vaccine access and uptake exist, particularly in low-resource settings, raising ethical concerns about equitable healthcare provision.

Another critical prophylactic vaccine is the Hepatitis B vaccine, which has been instrumental in reducing liver cancer incidence. Chronic Hepatitis B infection is a major risk factor for hepatocellular carcinoma (HCC), and widespread immunization has significantly decreased HCC rates globally (Chang et al., 2016). The success of the Hepatitis B vaccine highlights the importance of global vaccination programs, yet also underscores the need for sustained efforts to reach populations in regions where hepatitis B is endemic.

Therapeutic cancer vaccines represent a more recent development, focusing on enhancing the body's immune response to existing cancer cells. These vaccines typically target specific antigens on cancer cells. For example, the Sipuleucel-T vaccine, approved for prostate cancer, uses a patient's immune cells, modified ex vivo to attack prostate cancer cells (Kantoff et al., 2010). This approach, while promising, poses challenges in terms of cost, accessibility, and patient-specific customization, which can limit its widespread application.

Recent advancements in mRNA vaccine technology, accelerated by the COVID-19 pandemic, have opened new avenues for cancer vaccines. Companies like Moderna and BioNTech are pioneering personalized cancer vaccines, which are tailored to the unique mutations within an individual's tumour. These vaccines aim to stimulate an immune response specifically against the cancer's neoantigens, potentially leading to more effective treatments with fewer side effects (Verma et al., 2023). However, the rapid development and application of such technologies also raise ethical concerns regarding patient consent, data privacy, and the long-term implications of genetic manipulation.

The future of cancer vaccines appears promising, with ongoing research focusing on improving efficacy and broadening applications. The development of "off-the-shelf" vaccines targeting common mutations across various cancer types could democratize access to cancer immunotherapy, making these innovative treatments more accessible and cost-effective (Fan et al., 2023). However, the expansion of such technologies necessitates ongoing ethical considerations, particularly concerning equitable access and the management of adverse effects.

Lifestyle Modifications and Cancer Prevention

Lifestyle modifications play a pivotal role in cancer prevention by mitigating risk factors related to diet, physical activity, and smoking cessation. There is robust evidence indicating that lifestyle choices significantly impact cancer incidence, making these modifications a critical focus for public health interventions.

Dietary habits are foundational to cancer prevention. Diets rich in fruits, vegetables, whole grains, and legumes, coupled with low intake of red and processed meats, are associated with a reduced risk of several cancers, particularly colorectal cancer. The American Cancer Society (ACS) emphasizes the importance of following a healthy eating pattern that includes a variety of vegetables, fruits, and whole grains while limiting red and processed meats, sugar-sweetened beverages, and highly processed foods (Rock et al., 2020). The World Cancer Research Fund also provides similar dietary recommendations, highlighting that maintaining a healthy weight through proper diet and physical activity can prevent many types of cancer (Clinton et al, 2020). However, the implementation of these dietary recommendations often intersects with socio-economic and cultural factors, raising ethical concerns about access to healthy foods and the broader impact of dietary guidelines on diverse populations.

Physical activity is another vital component of cancer prevention. Regular physical activity has been shown to lower the risk of various cancers, including breast, colon, and endometrial cancers. The ACS recommends that adults engage in at least 150–300 minutes of moderate-intensity or 75–150 minutes

of vigorous-intensity physical activity per week. For children and adolescents, at least 60 minutes of moderate or vigorous daily activity is recommended (Rock et al., 2020). Physical activity not only helps maintain a healthy weight—critical given the link between obesity and an increased risk of 13 types of cancer (Molina-Montes et al., 2021)—but also improves overall physical and mental health. Despite these benefits, access to safe spaces for physical activity remains unequal, particularly in underserved communities, highlighting the need for public policies that address these disparities.

Smoking cessation remains the most significant modifiable risk factor for cancer prevention. Smoking is causally linked to several cancers, including lung, throat, mouth, esophagus, pancreas, and bladder. Comprehensive public health campaigns and smoking cessation programs have been successful in reducing smoking rates and, consequently, smoking-related cancers. Innovations such as mobile health (mHealth) interventions have proven effective in supporting smoking cessation, demonstrating the potential of technology in public health efforts (Palmer et al., 2018). However, the implementation of these technologies must consider ethical issues, such as privacy, data security, and the potential for unequal access to digital health tools.

Public health campaigns play a critical role in promoting lifestyle changes for cancer prevention. These campaigns educate the public about the benefits of a healthy diet, regular physical activity, and the risks associated with smoking. Interventions, such as community-based programs, policy changes to increase access to healthy foods, and the creation of safe spaces for physical activity, are essential strategies (Rock et al., 2020). However, the success of these campaigns often depends on their ability to reach diverse populations, necessitating culturally sensitive approaches and equitable resource allocation.

Evidence-based guidelines are essential for directing cancer prevention strategies through lifestyle modifications. Guidelines provided by organizations, such as the ACS and the World Cancer Research Fund, offer comprehensive recommendations for individuals and communities. These guidelines serve as a foundation for public health policies and individual behaviour changes aimed at reducing cancer risk (Clinton et al., 2020). As these guidelines evolve, it is crucial to address the ethical implications of their implementation, ensuring that they are inclusive and accessible to all segments of the population.

Advancements in Screening Technologies

Advancements in screening technologies have significantly transformed early cancer detection, with innovations such as liquid biopsy and AI-driven imaging analysis leading the way. Liquid biopsy, a minimally invasive test that detects cancer-related biomarkers in blood samples, presents an opportunity for early diagnosis and continuous monitoring of treatment responses. This technology is particularly advantageous for its ability to detect multiple types of cancer from a single blood draw, offering a less invasive alternative to traditional biopsies and enabling earlier intervention (Goodall et al., 2017).

For instance, cell-free DNA (cfDNA)-based screening is gaining traction as a sensitive tool for detecting mutations associated with cancers, such as lung and colorectal cancers, allowing for personalized treatment strategies (Siravegna et al., 2015). However, despite its promise, the implementation of liquid biopsies in clinical practice faces challenges, including the need for standardization, validation across diverse populations, and addressing false positives that could lead to unnecessary interventions.

Artificial Intelligence (AI) is another groundbreaking advancement revolutionizing cancer screening. AI algorithms, particularly in medical imaging, have demonstrated superior accuracy in interpreting images compared to human radiologists. For example, a study revealed that an AI algorithm achieved a sensitivity of 99% and a specificity of 97% in identifying breast cancer on mammograms, outperforming human experts (Al Muhaisen et al., 2024). Moreover, AI-driven tools are enhancing the accessibility of cancer screening through being integrated into mobile health units and community health centres. Such local integration is particularly beneficial to enhance access in underserved areas (Henderson et al., 2024).

However, the integration of AI into cancer screening is not without ethical concerns. Issues, such as data privacy, algorithmic bias, and the potential for over-reliance on technology at the expense of clinical judgement, must be carefully considered (Moleyar-Narayana et al., 2024). For instance, if an AI system disproportionately misinterprets images from certain demographic groups due to biased training data, it could exacerbate health disparities. Addressing these ethical concerns is crucial to ensure that AI integration into oncology practices benefits patients without compromising their rights (Zhang et al., 2023).

When comparing traditional screening methods to these new technologies, there has been a clear shift toward more efficient, less invasive, and potentially more cost-effective options. Traditional methods, such as mammography and colonoscopy, remain effective and widely used; however, technologies such as liquid biopsies and AI-driven diagnostics offer enhancements in accuracy, patient comfort, and accessibility. Despite their promise, these advancements also pose challenges, including high costs, regulatory hurdles, and the necessity for extensive validation studies to confirm their effectiveness and reliability in clinical practice (Babayan & Pantel, 2018). Ensuring equitable access to these cutting-edge technologies is paramount to avoiding a widening gap in healthcare outcomes between different socioeconomic groups.

Genetic and Genomic Screening for Cancer Susceptibility

The role of genetic and genomic screening in identifying cancer susceptibility has become increasingly significant due to advancements in technology and a deeper understanding of cancer's genetic basis. Genetic counselling and testing are now pivotal in cancer prevention and early detection, providing personalized risk assessments and tailored preventive strategies based on an individual's genetic profile.

Genetic counselling serves as a cornerstone in cancer prevention by helping individuals understand their hereditary risk. Counsellors gather detailed family histories and interpret genetic test results to provide risk assessments and recommendations for preventive measures. For instance, mutations in the BRCA1 and BRCA2 genes significantly elevate the risk of breast and ovarian cancers, prompting recommendations for enhanced surveillance or preventive surgeries for those carrying these mutations (Fund, 2021). Such proactive measures can drastically reduce cancer incidence in high-risk populations, illustrating the profound impact of genetic insights on patient outcomes.

Innovations in genomic technologies have further revolutionized cancer screening. Traditional methods (i.e., family history-based risk assessment) are now complemented by sophisticated tools, such as multigene panels and polygenic risk scores. These technologies assess multiple genetic variants simultaneously, providing a comprehensive risk profile that can guide personalized prevention strategies (Rajagopal et al., 2019). The increased availability of direct-to-consumer genetic tests has also made genetic information more accessible to the public. However, interpreting these results often requires professional genetic counseling to ensure individuals understand their implications and receive appropriate follow-up care (Fund, 2021). This accessibility raises ethical questions about informed consent, result interpretation, and potential psychological impacts, highlighting the need for professional guidance.

The ethical considerations in genetic and genomic screening are complex and multifaceted. Issues of privacy, informed consent, and the potential for genetic discrimination must be carefully managed. For example, the misuse of genetic information by employers or insurers could lead to discrimination, thus emphasizing the need for robust legal protection. Additionally, ensuring equitable access to genetic services is crucial, as historically underserved populations may have less access to these advancements. Efforts to broaden access and educate healthcare providers on genetic literacy are essential to mitigate disparities and ensure all individuals can benefit from these technologies (Rajagopal et al., 2019; Owens et al., 2019).

Moreover, as the field of genomic screening continues to evolve, ongoing research is needed to address the long-term implications of widespread genetic testing, particularly in relation to ethical and social issues. This includes understanding the psychological impact on individuals who learn they are at high risk of cancer and ensuring that all patients receive appropriate, culturally sensitive care.

IMPACT OF EARLY DETECTION ON PATIENT OUTCOMES

Early detection of cancer is pivotal in improving patient outcomes, with a strong correlation between early diagnosis and increased survival rates. The ability to identify cancer at a more manageable stage allows for timely intervention, leading to better prognoses and a wider array of treatment options. For example, studies have demonstrated that the 20-year survival rate for patients diagnosed with lung cancer via low-dose CT screening was 81%, with an impressive 95% survival rate for those diagnosed at Stage I (Henschke, 2023). This stands in stark contrast to the average 5-year survival rate of 18.6% for lung cancer patients diagnosed at later stages, underscoring the critical importance of early detection (Radiological Society of North America, 2023).

Moreover, the quality of life for cancer patients is significantly enhanced when the disease is detected early. Early diagnosis often leads to less aggressive treatment protocols, reducing both the physical and psychological burdens on patients. For instance, patients with early-stage non-small-cell lung cancer (NSCLC) typically require only surgical intervention, avoiding the more severe side effects and complications associated with chemotherapy and radiation treatments needed in later stages (Crosby et al., 2022). This not only improves survival rates but also preserves the overall well-being of patients, allowing them to maintain a higher quality of life during and after treatment.

Public health initiatives promoting early cancer detection have demonstrated substantial success, particularly in screening programs for cancers such as breast, colorectal, and cervical cancers. These programs have been instrumental in catching these diseases at more treatable stages, thereby improving survival rates and reducing mortality. However, the effectiveness of these programs varies significantly depending on the type of cancer and the demographic characteristics of the screened population. For example, mammographic screening has shown a stronger impact on mortality reduction in women over 50 compared to younger women, where the evidence remains less conclusive (Gorski & Gorski, 2008).

Despite the advancements in early detection, the challenges of lead-time and length biases in screening persist. These biases can create an illusion of improved survival without actual benefits, complicating the evaluation of new screening technologies. Lead-time bias occurs when early detection increases the period during which a disease is known without necessarily improving the actual outcome, while length bias refers to the preferential detection of slower progression, less aggressive cancers, which might not have caused harm if left undetected (Gorski & Gorski, 2008). Addressing these biases is crucial for assessing the true benefits of early detection programs accurately and ensuring that resources are directed toward the most effective interventions.

ETHICAL CONSIDERATIONS IN CANCER PREVENTION AND SCREENING

Ethical considerations in cancer prevention and screening are critical to ensuring that these practices are just, equitable, and respectful of patient rights. Key areas of focus include informed consent, patient autonomy, equity and access, and balancing the benefits and harms of screening programs.

Informed consent is a foundational ethical principle in cancer screening, requiring that patients make knowledgeable decisions about their participation. Effective informed consent involves providing patients with comprehensive information about the benefits, risks, and uncertainties associated with screening procedures. For example, in prostate cancer

screening, patients must be aware of the potential for false positives and the psychological and physical consequences of subsequent diagnostic interventions (Juth & Munthe, 2013). Ensuring that patients understand these factors respects their autonomy, allowing them to make choices aligned with their values and preferences (Sterba et al., 2017).

Equity and access are equally crucial in the ethical landscape of cancer prevention and screening. Disparities in healthcare access can lead to unequal screening opportunities, disproportionately affecting underserved populations. To ensure equitable access, it is necessary to address socioeconomic barriers and implement policies that provide screening services to all demographic groups, especially those that have been historically marginalized (Akers et al., 2007). Public health campaigns and community-based interventions are essential strategies to enhance accessibility and encourage participation across diverse populations (Sterba et al., 2017). Moreover, technological innovations should be introduced in a way that promotes rather than hinders equitable access to high-quality care.

Balancing the benefits and harms of screening programs is another ethical challenge. Screening programs should be designed to maximize benefits—such as early detection and improved survival rates—while minimizing potential harm, such as overdiagnosis, overtreatment, and anxiety from false positives. For example, age-specific and race-specific thresholds in prostate-specific antigen (PSA) testing are used to improve the balance between sensitivity and specificity, reducing unnecessary biopsies and associated harms (Björklund et al., 2010). Screening protocols must be continuously evaluated and adjusted based on emerging evidence to maintain this delicate balance (Chen et al., 2018).

The integration of new technologies in screening, such as AI-driven imaging and genomic testing, introduces additional ethical considerations. While these technologies promise enhanced accuracy and personalized risk assessments, they also raise concerns about data privacy, the potential for genetic discrimination, and the risk of exacerbating existing healthcare disparities (Ghazali et al., 2017). It is essential that ethical frameworks guide the implementation of these innovations to ensure they benefit all patients equitably, without introducing new forms of inequality or compromising patient rights.

Ethical considerations in cancer prevention and screening are inherently complex and multifaceted. Ongoing dialogue among healthcare providers, policymakers, and patients is necessary to navigate these challenges effectively. By prioritizing informed consent, equity, and a balanced approach to benefits and harms, the medical community can develop and sustain ethically sound screening programs that enhance patient outcomes and maintain trust in the healthcare system.

ROLE OF ONCOLOGY NURSING IN PREVENTION AND EARLY DETECTION

Oncology nurses can play a pivotal role in cancer prevention and early detection, given their continuous patient interaction and their trusted status within the healthcare team (Baileys et al., 2018). Not only are there many opportunities during daily interactions with patient and families, but nurses are uniquely positioned to lead and implement various interventions and educational programs that encourage patients to engage in preventive behaviours and participate in early detection efforts. For example, oncology nurses routinely guide patients through complex decision-making processes, offering personalized advice and ensuring that patients understand the implications of screening results and prevention strategies.

Nurse-led initiatives have been particularly successful in increasing early cancer detection rates, which directly correlates with improved patient outcomes and reduced mortality (Oncology Nursing Society, 2018). These programs often involve the administration of routine screenings, such as mammograms, colonoscopies, and HPV tests, which are critical in identifying cancers at a more treatable stage. Additionally, oncology nurses can play a crucial role in public health campaigns that promote lifestyle changes, such as smoking cessation, dietary adjustments, and increased physical activity—all of which are known to reduce cancer risk (Friebel-Klingner et al., 2024).

The integration of AI into oncology nursing is an emerging area of interest. AI tools can assist nurses in assessing patient risk factors, determining eligibility for specific screening programs, and even predicting patient outcomes based on large datasets. However, the adoption of AI in oncology nursing also raises ethical concerns, particularly regarding data privacy, the potential for algorithmic bias, and the risk of over-reliance on technology. Nurses must therefore be trained not only in the use of these technologies but also in understanding their limitations to maintain patient-centred care.

Continuing education and professional development are vital for oncology nurses to remain up-to-date with the latest advancements in cancer prevention and early detection. Certifications and training programs, such as those offered by the Oncology Nursing Society (ONS), ensure that nurses are equipped with the latest knowledge and skills necessary to implement effective prevention strategies (Baileys et al., 2018). By staying current with emerging technologies and evidence-based practices, oncology nurses can continue to lead efforts in reducing cancer incidence and improving patient outcomes.

PUBLIC HEALTH POLICIES AND CANCER PREVENTION

Public health policies are instrumental in shaping cancer prevention strategies and frameworks, guiding both governmental and non-governmental actions. Comprehensive cancer prevention programs are often initiated at the governmental level, such as New York State's "Prevention Agenda 2019-2024," which emphasizes chronic disease prevention through promoting healthy eating, physical activity, and tobacco prevention—factors crucial in reducing cancer risk (New York State Department of Health, 2019). These policies underscore the importance of coordinated public health strategies in mitigating cancer incidence on a large scale.

In addition to governmental efforts, non-governmental organizations (NGOs) and professional bodies, such as the

ONS, play a crucial role in cancer prevention advocacy. The ONS, for example, actively engages in policy advocacy to influence cancer prevention and care at the legislative level. Their initiatives, like Capitol Hill Days, bring oncology nurses to Washington, D.C., to advocate for policies that support cancer prevention and patient care (Oncology Nursing Society, 2018). These efforts highlight the significant impact that professional organizations can have on shaping public health policies and advancing cancer prevention.

The integration of AI and other technologies into public health initiatives presents new opportunities and challenges. AI can enhance the effectiveness of public health campaigns by targeting interventions more precisely and by analyzing large-scale data to identify trends and at-risk populations. However, the use of AI also necessitates careful consideration of ethical issues, such as ensuring equitable access to these technologies and preventing disparities in their implementation. Policymakers must therefore work to balance the benefits of technological advancements with the ethical implications they entail.

Policy changes can significantly impact screening rates and the accessibility of preventive services. For example, the Affordable Care Act (ACA) in the United States has been instrumental in increasing cancer screening uptake, leading to earlier detection and improved outcomes (Preston et al., 2024). Such policies serve as models for successful public health interventions that can be adapted and implemented in other regions to enhance cancer prevention efforts.

FUTURE DIRECTIONS AND RESEARCH IN CANCER PREVENTION AND EARLY DETECTION

The future of cancer prevention and early detection is set to be shaped by significant advancements in molecular biology, technological innovation, and collaborative research. These advancements hold the promise of improving patient outcomes by enabling earlier and more accurate diagnoses, but they also introduce new challenges that must be carefully managed.

A key emerging trend is the integration of molecular biology with cutting-edge technology to refine cancer detection methods. Researchers are increasingly focused on identifying early molecular changes and biomarkers that can serve as indicators of cancer long before clinical symptoms appear. For instance, advancements in understanding the genetic and epigenetic alterations that precede tumour formation are leading to the development of non-invasive tests capable of detecting these changes at a very early stage (Nalley, 2020). These molecular insights are critical for the creation of diagnostic tools that can identify cancer in its infancy, thereby allowing for timely intervention.

Technological innovations are playing a central role in this evolution. Liquid biopsies, which detect cancer through the analysis of bodily fluids, represent a major breakthrough in non-invasive diagnostics. These tests can identify circulating tumour DNA (ctDNA) and other cancer-related markers, offering a real-time view of tumour dynamics and enabling the early detection of multiple cancer types. This technology is not only less invasive than traditional biopsies but also allows for ongoing monitoring of cancer progression or recurrence (Connal et al., 2023). However, the widespread adoption of liquid biopsies poses challenges, including ensuring their accuracy across diverse populations and integrating them into existing clinical workflows without exacerbating healthcare disparities.

AI-driven diagnostic tools are another frontier in early cancer detection. These tools are increasingly being used to analyze complex medical imaging data with unprecedented speed and accuracy. For example, AI algorithms can now detect subtle changes in imaging that might be overlooked by human radiologists, thereby facilitating earlier diagnosis and improving the chances of successful treatment. However, the integration of AI into clinical practice raises important ethical considerations, particularly regarding the potential for algorithmic bias and the need to maintain human oversight to ensure patient safety and trust.

The Cancer Moonshot initiative exemplifies the transformative potential of collaborative research and data sharing. By fostering partnerships among researchers, clinicians, and patient advocacy groups, the initiative is driving forward the development of innovative cancer prevention and detection strategies (National Cancer Institute, 2021). The emphasis on "radical data sharing" within this initiative underscores the importance of breaking down traditional silos in cancer research, thereby accelerating the pace of discovery and the translation of findings into clinical practice.

Looking ahead, one of the critical challenges will be ensuring equitable access to these advanced technologies. As innovations in early detection become more sophisticated, there is a risk that they may not be equally available to all populations, particularly those in low-resource settings. Policymakers and healthcare providers must work together to address these disparities and ensure that all patients can benefit from the latest advancements in cancer care. Additionally, there is an ongoing need to balance the benefits of early detection with the risks of overdiagnosis and overtreatment, which can lead to unnecessary interventions and increased patient anxiety (Harvard T.H. Chan School of Public Health, 2023). Future research should therefore focus not only on improving the accuracy of diagnostic tools, but also on developing guidelines that help clinicians and patients make informed decisions about treatment options based on the diagnostic results.

CONCLUSION

In conclusion, the field of oncology has seen significant advancements in the areas of cancer prevention and early detection, driven by innovations such as cancer vaccines, lifestyle interventions, and new screening technologies. These developments have already made a substantial impact on patient outcomes, as evidenced by increased survival rates and improved quality of life associated with early diagnosis. The role of oncology nursing is central to the successful implementation of these strategies, as nurses provide essential patient education, lead screening initiatives, and ensure that ethical considerations are addressed in clinical practice. Public health policies also play a critical role by facilitating the equitable

distribution of preventive care and supporting the integration of new technologies into routine practice.

As research continues to advance, the future of cancer prevention and early detection is poised to be shaped by the integration of genetic and genomic screening, AI-driven diagnostics, and non-invasive testing methods like liquid biopsies. These innovations promise to further revolutionize oncology by enabling even earlier and more precise detection of cancer. However, the successful adoption of these technologies will require ongoing collaboration across the healthcare sector, robust data sharing practices, and careful consideration of ethical implications. By continuing to adapt and refine these approaches, the medical community can ensure that the benefits of these advancements are realized by all patients, ultimately leading to improved cancer care and outcomes.

COMPETING INTERESTS

The authors declare that they have no competing interests.

REFERENCES

Akers, A. Y., Newmann, S. J., & Smith, J. S. (2007). Factors underlying disparities in cervical cancer incidence, screening and treatment in the United States. *Current Problems in Cancer, 31*(3), 157–181. https:doi.org/10.1016/j.current cancer.2007.01.001

Al Muhaisen, S., Safi, O., Ulayan, A., Aljawamis, S., Fakhoury, M., Baydoun, H., & Abuquteish, D. (2024). Artificial intelligence-powered mammography: Navigating the landscape of deep learning for breast cancer detection. *Cureus, 16*(3), e56945. https://doi.org/10.7759/cureus.56945

Arbyn, M., Xu, L., Simoens, C., & Martin-Hirsch, P. P. (2020). Prophylactic vaccination against human papillomaviruses to prevent cervical cancer and its precursors. *Cochrane Database of Systematic Reviews*, (5), CD009069. https://doi.org/10.1002/14651858.CD009069.pub3

Baileys, K., McMullen, L., Lubejko, B., Christensen, D., Haylock, P. J., Rose, T., Sellers, J., & Srdanovic, D. (2018). Nurse navigator core competencies: An update to reflect the evolution of the role. *Clinical Journal of Oncology Nursing, 22*(3), 272–281. https://doi.org/10.1188/18.CJON.272-281

Björklund, M., Sarvimäki, A., & Berg, A. (2010). Living with head and neck cancer: A profile of captivity. *Journal of Nursing and Healthcare of Chronic Illness, 2*(1), 22–31. https://doi.org/10.1111/j.1752-9824.2010.01042.x

Chang, M. H., You, S. L., Chen, C. J., Liu, C. J., Lai, M. W., Wu, T. C., Wu, S. F., Lee, C. M., Yang, S. S., Chu, H. C., Wang, T. E., Chen, B. W., Chuang, W. L., Soon, M. S., Lin, C. Y., Chiou, S. T., Kuo, H. S., Chen, D. S., Yang, Y. J., ... Cheng, Y. S. (2016). Long-term effects of hepatitis B immunization of infants in preventing liver cancer. *Gastroenterology, 151*(3), 472–480.e1. https://doi.org/10.1053/j.gastro.2016.05.048

Chen, A. M., Hsu, S., Felix, C., Garst, J., & Yoshizaki, T. (2018). Effect of psychosocial distress on outcome for head and neck cancer patients undergoing radiation. *Laryngoscope, 128*(3), 641–645. https://doi.org/10.1002/lary.26751

Clinton, S. K., Giovannucci, E. L., & Hursting, S. D. (2020). The World Cancer Research Fund/American Institute for Cancer Research third expert report on diet, nutrition, physical activity, and cancer: Impact and future directions. *The Journal of Nutrition, 150*(4), 663–671. https://doi.org/10.1093/jn/nxz268

Connal, S., Cameron, J. M., Sala, A., Brennan, P. M., Palmer, D. S., Palmer, J. D., Perlow, H., & Baker, M. J. (2023). Liquid biopsies: The future of cancer early detection. *Journal of Translational Medicine, 21*(1), 118. https://doi.org/10.1186/s12967-023-03960-8

Crosby, D., Bhatia, S., Brindle, K. M., Coussens, L. M., Dive, C., Emberton, M., Esener, S., Fitzgerald, R. C., Gambhir, S. S., Kuhn, P., Rebbeck, T. R., & Balasubramanian, S. (2022). Early detection of cancer. *Science, 375*(6586), eaay9040. https://doi.org/10.1126/science.aay9040

Dillner, J. (2019). Early detection and prevention. *Molecular Oncology, 13*(3), 591–598. https://doi.org/10.1002/1878-0261.12459

Division of Cancer Prevention. (2024). *Early detection. National Cancer Institute.* https://prevention.cancer.gov/research-groups/early-detection

Fan, T., Zhang, M., Yang, J., Zhu, Z., Cao, W., & Dong, C. (2023). Therapeutic cancer vaccines: Advancements, challenges, and prospects. *Signal Transduction and Targeted Therapy, 8*(1), 450. https://doi.org/10.1038/s41392-023-01674-3

Friebel-Klingner, T. M., Alvarez, G. G., Lappen, H., Pace, L. E., Huang, K. Y., Fernández, M. E., Shelley, D., & Rositch, A. F. (2024). State of the science of scale-up of cancer prevention and early detection interventions in low- and middle-income countries: A scoping review. *JCO Global Oncology, 10*, e2300238. https://doi.org/10.1200/GO.23.00238

Fund, J. (2021, April 20). *How can genetic testing help early detection, risk reduction, and prevention of cancer?* Jimmy Fund Blog. https://blog.jimmyfund.org/2021/02/how-can-genetic-testing-help-early-detection-risk-reduction-and-prevention-of-cancer/

Garland, S. M., Kjaer, S. K., Muñoz, N., Block, S. L., Brown, D. R., DiNubile, M. J., Lindsay, B. R., Kuter, B. J., Perez, G., Dominiak-Felden, G., Saah, A. J., Drury, R., Das, R., & Velicer, C. (2016). Impact and effectiveness of the Quadrivalent Human Papillomavirus Vaccine: A systematic review of 10 years of real-world experience. *Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America*, 63(4), 519–527. https://doi.org/10.1093/cid/ciw354

Genome Medicine. (2023). *Advances in liquid biopsy approaches for early detection and monitoring of cancer*. https://genomemedicine.biomedcentral.com/articles/10.1186/s13073-018-0547-1

Ghazali, N., Roe, B., Lowe, D., Tandon, S., Jones, T., Shaw, R., Risk, J., & Rogers, S. N. (2017). Using the patients concerns inventory for distress screening in post-treatment head and neck cancer survivors. *Journal of Cranio-Maxillofacial Surgery/Journal of Cranio-Maxillo-Facial Surgery, 45*(10), 1743–1748. https://doi.org/10.1016/j.jcms.2017.07.009

Goodall, J., Mateo, J., Yuan, W., Mossop, H., Porta, N., Miranda, S., Perez-Lopez, R., Dolling, D., Robinson, D. R., Sandhu, S., Fowler, G., Ebbs, B., Flohr, P., Seed, G., Rodrigues, D. N., Boysen, G., Bertan, C., Atkin, M., Clarke, M., ... TOPARP-A Investigators. (2017). Circulating cell-free DNA to guide prostate cancer treatment with PARP inhibition. *Cancer Discovery, 7*(9), 1006–1017. https://doi.org/10.1158/2159-8290.CD-17-0261

Gorski, D., & Gorski, D. (2008, May 11). *The early detection of cancer and improved survival: More complicated than most people think*. Science-Based Medicine. https://sciencebasedmedicine.org/the-early-detection-of-cancer-and-improved-survival-more-complicated-than-most-people-think/

Harvard T.H. Chan School of Public Health. (2023). *The future of cancer prevention (part 1)*. https://www.hsph.harvard.edu/news/multimedia-article/cancer-prevention-podcast/

Henderson, J. T., Webber, E. M., Weyrich, M., Miller, M., & Melnikow, J. (2024, April 1). *Screening for breast cancer: A comparative effectiveness review for the U.S. Preventive Services Task Force*. NCBI Bookshelf. https://www.ncbi.nlm.nih.gov/books/NBK603791/#ch4.s1

Henschke, C. (2023). *Screening sharply improves lung cancer long-term survival*. Radiological Society of North America (RSNA). https://www.rsna.org/news/2023/november/screening-improves-lung-cancer-survival

Juth, N., & Munthe, C. (2013). *The ethics of screening in health care and medicine*. The international library of ethics, law, and the new medicine. https://doi.org/10.1007/978-94-007-2045-9

Kantoff, P. W., Higano, C. S., Shore, N. D., Berger, E. R., Small, E. J., Penson, D. F., Redfern, C. H., Ferrari, A. C., Dreicer, R., Sims, R. B., Xu, Y., Frohlich, M. W., & Schellhammer, P. F. (2010). Sipuleucel-T immunotherapy for castration-resistant prostate cancer. *New England Journal of Medicine*, *363*(5), 411–422. https://doi.org/10.1056/nejmoa1001294

Levin, B., Lieberman, D. A., McFarland, B., Smith, R. A., Brooks, D., Andrews, K. S., Dash, C., Giardiello, F. M., Glick, S., Levin, T. R., Pickhardt, P., Rex, D. K., Thorson, A., & Winawer, S. J. (2008). Screening and surveillance for the early detection of colorectal cancer and adenomatous polyps, 2008: A Joint Guideline from the American Cancer Society, the US Multi-Society Task Force on Colorectal Cancer, and the American College of Radiology. *CA: A Cancer Journal for Clinicians*, *58*(3), 130–160. https://doi.org/10.3322/ca.2007.0018

Moleyar-Narayana, P., Leslie, S. W., & Ranganathan, S. (2024). Cancer screening. In *StatPearls*. StatPearls Publishing. https://www.ncbi.nlm.nih.gov/books/NBK563138/

Molina-Montes, E., Ubago-Guisado, E., Petrova, D., Amiano, P., Chirlaque, M. D., Agudo, A., & Sánchez, M. J. (2021). The role of diet, alcohol, BMI, and physical activity in cancer mortality: Summary findings of the EPIC Study. *Nutrients*, *13*(12), 4293. https://doi.org/10.3390/nu13124293

Nalley, C. (2020). A precision approach to cancer prevention & early detection. *Oncology Times*, *42*(19), 27,31-31. https://doi.org/10.1097/01.cot.0000719340.05040.ea

National Cancer Institute. (2021, January 11). *The Cancer Moonshot: A Midpoint Progress Update*. https://www.cancer.gov/news-events/cancer-currents-blog/2021/cancer-moonshot-midpoint-progress-update

National Cancer Institute. (2024, February 21). *NCI launches research network to evaluate emerging cancer screening technologies*. [Press release]. https://www.cancer.gov/news-events/press-releases/2024/cancer-screening-research-network-launches

New York State Department of Health. (2019). *Prevention agenda 2019–2024: New York State's health improvement plan*. https://www.health.ny.gov/prevention/prevention_agenda/2019-2024/

NHS England. (2019). *NHS long term plan ambitions for cancer*. https://www.england.nhs.uk/cancer/strategy/

Oncology Nursing Society (ONS). (2018). Role of the oncology nurse navigator throughout the cancer trajectory. *Oncology Nursing Forum*, *45*(3), 283. https://doi.org/10.1188/18.ONF.283

Palmer, M., Sutherland, J., Barnard, S., Wynne, A., Rezel, E., Doel, A., Grigsby-Duffy, L., Edwards, S., Russell, S., Hotopf, E., Perel, P., & Free, C. (2018). The effectiveness of smoking cessation, physical activity/diet and alcohol reduction interventions delivered by mobile phones for the prevention of non-communicable diseases: A systematic review of randomised controlled trials. *PloS One*, *13*(1), e0189801. https://doi.org/10.1371/journal.pone.0189801

American Cancer Society. (n.d.). *Prevention and Early Detection Guidelines*. https://www.cancer.org/health-care-professionals/american-cancer-society-prevention-early-detection-guidelines.html

Rajagopal, P. S., Nielsen, S., & Olopade, O. I. (2019). USPSTF Recommendations for BRCA1 and BRCA2 testing in the context of a transformative national cancer control plan. *JAMA Network Open*, *2*(8), e1910142. https://doi.org/10.1001/jamanetworkopen.2019.10142

Rock, C. L., Thomson, C., Gansler, T., Gapstur, S. M., McCullough, M. L., Patel, A. V., Andrews, K. S., Bandera, E. V., Spees, C. K., Robien, K., Hartman, S., Sullivan, K., Grant, B. L., Hamilton, K. K., Kushi, L. H., Caan, B. J., Kibbe, D., Black, J. D., Wiedt, T. L., … Doyle, C. (2020). American Cancer Society guideline for diet and physical activity for cancer prevention. *CA: A Cancer Journal for Clinicians*, *70*(4), 245–271. https://doi.org/10.3322/caac.21591

Siravegna, G., Mussolin, B., Buscarino, M., Corti, G., Cassingena, A., Crisafulli, G., Ponzetti, A., Cremolini, C., Amatu, A., Lauricella, C., Lamba, S., Hobor, S., Avallone, A., Valtorta, E., Rospo, G., Medico, E., Motta, V., Antoniotti, C., Tatangelo, F., … Bardelli, A. (2015). Clonal evolution and resistance to EGFR blockade in the blood of colorectal cancer patients. *Nature Medicine*, *21*(7), 795–801. https://doi.org/10.1038/nm.3870

Sterba, K. R., Zapka, J., LaPelle, N., Garris, T. K., Buchanan, A., Scallion, M., & Day, T. (2017). Development of a survivorship needs assessment planning tool for head and neck cancer survivors and their caregivers: A preliminary study. *Journal of Cancer Survivorship*, *11*(6), 822–832. https://doi.org/10.1007/s11764-017-0621-4

US Preventive Services Task Force, Owens, D. K., Davidson, K. W., Krist, A. H., Barry, M. J., Cabana, M., Caughey, A. B., Doubeni, C. A., Epling, J. W., Jr, Kubik, M., Landefeld, C. S., Mangione, C. M., Pbert, L., Silverstein, M., Simon, M. A., Tseng, C. W., & Wong, J. B. (2019). Risk assessment, genetic counseling, and genetic testing for BRCA-related cancer: US Preventive Services Task Force recommendation statement. *JAMA*, *322*(7), 652–665. https://doi.org/10.1001/jama.2019.10987

Verma, C., Pawar, V. A., Srivastava, S., Tyagi, A., Kaushik, G., Shukla, S. K., & Kumar, V. (2023). Cancer vaccines in the immunotherapy era: Promise and potential. *Vaccines*, *11*(12), 1783. https://doi.org/10.3390/vaccines11121783

Zhang, B., Shi, H., & Wang, H. (2023). Machine learning and AI in cancer prognosis, prediction, and treatment selection: A critical approach. *Journal of Multidisciplinary Healthcare*, *16*, 1779–1791. https://doi.org/10.2147/JMDH.S410301